Histone deacetylase inhibitors: From bench to clinic

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1505-1529

  Paris, Marielle ^a   Porcelloni, Marina ^a   Binaschi, Monica ^a   Fattori, Daniela ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOPHENYLAMIDE; ALKANOIC ACID; AMINO ACID; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE 5 HYDROXAMIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN 2 HYDROXAMIC ACID DERIVATIVE; CARBAMIC ACID; CINNAMOYLHYDROXAMIC ACID DERIVATIVE; CINNAMOYLPYRROLE DERIVATIVE; CYSTEINE; DIAMINE; DIGLYCINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; PHENYL HYDROXAMATE DERIVATIVE; PYRROLE DERIVATIVE; SIRTUIN; SULFONAMIDE; THIAZOLYLTHIOPHENE; THIOL DERIVATIVE; THIOPHENE; THIOUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

APOPTOSIS; CANCER GROWTH; CATALYSIS; CELL SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME ACTIVITY; HEALTH CENTER; HUMAN; IC 50; IN VITRO STUDY; KIDNEY CARCINOMA; MELANOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 41149089267     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7011408     Document Type: Review

References (180)

1. Marks, P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 1351-1356.
2. (a) Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanism of action. Oncogene 2007, 26, 5541-5552.
3. (b) Price, S.; Dyke, H. J. Histone deacetylase inhibitors: an analysis of recent patenting activity. Expert Opin. Ther. Pat. 2007, 17, 745-765.
4. (c) Marchion, D.; Münster, P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 2007, 7, 583-598.
5. (d) Gallinari, P.; Di Marco, S.; Jones, P.; Pallaoro, M.; Steinkuhler, C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007, 17, 195-211.
6. (e) Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
7. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 5097-5116.
8. Data obtained from Thomson Pharma (www.thomson-pharma.com).
9. (a) De Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
10. (b) Voelter-Mahlknecht, S.; Ho, A. D.; Mahlknecht, U. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int. J. Mol. Med. 2005, 16, 589-598.
11. Michan, S.; Sinclair, D. Sirtuin in mammals: insights into their biological function. Biochem. J. 2007, 404, 1-13.
12. (a) Bernstein, B. E.; Tong, J. K.; Schreiber, S. L. Genomewide studies of histone deacetylase function in yeast. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13708-13713.
13. (b) Sun, Z. W.; Hampsey, M. A general requirement for the Sin3-Rpd3 histone deacetylase complex in regulating silencing in Saccharomyces cerevisiae. Genetics 1999, 152, 921-932.
14. Foglietti, C.; Filocamo, G.; De Rinaldis, E.; Lahm, A.; Cortese, R.; Steinkuhler, C. Dissecting the biological function of Drosophila histone deacetylase by RNA interference and transcriptional profiling. J. Biol. Chem. 2006, 281, 17968-17976.
15. (a) Lagger, G.; O'Carrol, D.; Rembold, M.; Khier, H.; Tishler, J.; Weitzer, G.; Schuettengruber, B.; Hauser, C.; Brunmeier, R.; Jenuwein, T.; Seiser, C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002, 21, 2672-2681.
16. (b) Zupkovitz, G.; Tishler, J.; Posch, M.; Sadzak, I.; Ramsauer, K.; Egger, G.; Grausenburger, R.; Schweifer, N.; Chiocca, S.; Decker, T.; Seiser, C. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol. Cell. Biol. 2006, 26, 7913-7928.
17. Montgomery, R. L.; Davis, C. A.; Potthoff, M. J.; Haberland, M.; Fielitz, J.; Qi, X.; Hill, J. A.; Richardson, J. A.; Olson, E. N. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth and contractility. Genes Dev. 2007, 21, 1790-1802.
18. Li, Y.; Kao, G. D.; Garcia, B. A.; Shabanowitz, J.; Hunt, D. F.; Quin, J.; Phelan, C.; Lazar, M. A. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev. 2006, 20, 2566-2579.
19. (a) Waltregny, D.; de Levai, L.; Glénisson, W.; Tran, S. L.; North, B. J.; Bellahcène, A.; Weidle, U.; Verdin, E.; Castronovo, V. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in human normal tissues. Am. J. Pathol. 2004, 165, 553-564.
20. (b) Waltregny, D.; Glénisson, W.; Tran, S. L.; North, B. J.; Verdin, E.; Colige, A.; Castronovo, V. HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility. FASEB J. 2005, 19, 966-968.
21. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19, 286-293.
22. Vega, R. B.; Matsuda, K.; Barbosa, A. C.; Yang, X.; Meadows, E.; McAnally, J.; Pomajzi, C.; Shelton, J. M.; Richardson, J. A.; Karsenty, G.; Olson, E. N. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119, 555-556.
23. Bolger, T. A.; Yao, T.-P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci. 2005, 25, 9544-9553.
24. Dequiedt, F.; Kasler, H.; Fischle, W.; Kiermer, V.; Weinstein, M.; Herndier, B. G.; Verdin, E. HDAC 7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003, 18, 687-698.
25. (a) Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, J. A.; Olson, E. N. Class II histone deactylases act as signal-responsive repressors of cardiaczto hypertrophy. Cell 2002, 110, 479-488.
26. (b) Chang, S.; McKinsey, T. A.; Zhang, C. L.; Richardson, J. A.; Hill, J. A.; Olson, E. N. Histone deacetylses 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 2004, 24, 8467-8476.
27. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC 6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22, 1168-1179.
28. Kovacs, J. J.; Murphy, P. J. M.; Gaillard, S.; Zaho, X.; Wu, J.-T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T.-P. HDAC 6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18, 601-607.
29. Warrel, R. P.; He, L.-Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocitic leukemia by use of an inhibitor of histone deacetylases. J. Natl. Cancer Inst. 1998, 90, 1621-1625.
30. (a) Bereshchenko, O. R.; Gu, W.; Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 2002, 32, 606-613.
31. (b) Pasqualucci, L.; Bereshchenko, O. R.; Niu, H.; Klein, U.; Basso, K.; Guglielmino, R.; Cattoretti, G.; Dalla-Favera, R. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk. Lymphoma 2003, 44, S5-S12.
32. Wang, J.; Hoshino, T.; Redner, R. L.; Kajigaya, S.; Liu, J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10860-10865.
33. (a) Song, J.; Noh, J. H.; Lee, J. H.; Eun, J. W.; Kim, S. Y.; Lee, S. H.; Park, W. S.; Yoo, N. J.; Lee, J. Y.; Nam, S. W. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005, 113, 264-268.
34. (b) Sasaki, H.; Moriyama, S.; Nakashima, Y.; Kobayashi, Y.; Kiriyama, M.; Fukai, I.; Yamakawa, Y.; Fuji, Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46, 171-178.
35. (c) Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K.-P.; Gottlicher, M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5, 455-463.
36. (a) Senese, S.; Zaragosa, K.; Minardi, S.; Muradore, I.; Ronzoni, S.; Passafaro, A.; Bernard, L.; Draetta, G. F.; Alcalay, M.; Seiser, C.; Chiocca, S. Role for histone deacetylase 1 in human tumor cell roliferation. Mol. Cell. Biol. 2007, 13, 4784-95.
37. (b) Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R.-Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003, 310, 529-536.
38. (a) Sasaki, H.; Moriyama, S.; Nakashima, Y.; Kobayashi, Y.; Kiriyama, M.; Fukai, I.; Yamakawa, Y.; Fuji, Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46, 171-178.
39. (b) Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K.-P.; Gottlicher, M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5, 455-463.
40. (a) Huang, B. H.; Laban, M.; Leung, C. H.; Lee, L.; Lee, C. K.; Salto-Tellez, M.; Raju, G. C.; Hooi, S. C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12, 395-404.
41. (b) Harms, K. L.; Chen, X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007, 67, 3145-3152.
42. Qian, D. Z.; Kachhap, S. K.; Collis, S. J.; Verheul, H. M. W.; Carducci, M. A.; Atadja, P.; Pili, R. Class II histone deacetylase are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res. 2006, 66, 8814-8821.
43. Chauchereau, A.; Mathieu, M.; de Saintignon, J.; Ferreira, R.; Pritchard, L. L.; Mishal, Z.; Dejean, A.; Harel-Bellan, A. HDAC4 mediates transcriptional repression by the acute promyelocytic leukemia-associated protein PLZF. Oncogene 2004, 23, 8777-8784.
44. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylases inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769-784.
45. Faraco, G.; Pancani, T.; Formentini, L.; Mascagni, P.; Fossati, G.; Leoni, F.; Chiarugi, A. Pharmacological inhibition of histone deacetylase by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70, 1876-1884.
46. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62, 4916-4921.
47. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Mainer, T.; Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer 2007, 121, 1138-1148.
48. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structure of a histone deacetylase homologue bound to TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
49. (a) Vannini, A.; Volpari, C.; Filocamo, G.; Caroli Casavola, E.:; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA. 2004, 101, 15064-15069.
50. (b) Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insight into class I histone deacetylases. Structure 2004, 12, 1325-1334.
51. Wang, D.-F.; Wiest, O.; Helquist, P.; Lan-Hargest, H.-Y.; Wiech, N. L. On the function of the 14 Å long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J. Med. Chem. 2004, 47, 3400-3417.
52. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Fiener, R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 2005, 354, 107-120.
53. Wang, D.-F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitors design: homology modeling, docking studies, and molecular dynamic simulations of human class i histone deacetylases. J. Med. Chem. 2006, 49, 6936-6947.
54. Gantt, S. L.; Fierke, C. A. Probing the Catalytic Mechanism of Human Histone Deacetylase 8. Presented at the 232nd National Meeting of the American Chemical Society. 2006; BIOL255.
55. Gannt, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 2006, 45, 6170-6178.
56. Belvedere, S.; Witter, D. J.; Yan, Y.; Secrist, P.; Richon, V.; Miller, T. A. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 3969-3971.
57. (a) Belvedere, S.; Methot, J. L.; Miller, T. A.; Witter, D. J.; Yan, J. Histone Deacetylase Inhibitors. WO2006017215, 2006.
58. (b) Belvedere, S.; Hamblett, C. L.; Miller, T. A.; Witter, D. J.; Yan, J. Histone Deacetylase Inhibitors. WO2006017216, 2006.
59. (c) Belvedere, S.; Hamblett, C. L.; Miller, T. A.; Witter, D. J.; Yan, J. Histone Deacetylase Inhibitors. WO2006026260, 2006.
60. Miller, T. A.; Witter, D. J.; Belvedere, S. Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives. WO2005053610, 2005.
61. Dai, Y.; Guo, Y.; Curtin, M. L.; Li, J.; Pease, L. J.; Guo, J.; Marcotte, P. A.; Glaser, K. B.; Davidsen, S. K.; Michaelides, M. R. A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg. Med. Chem. Lett. 2003, 13, 3817-3820.
62. Cho, J. W.; Lim, S. C.; Maeng, C. Y.; Hwang, S. G.; Bae, S. J.; Kim, E. A. Oxazole Hydroxamic Acid Derivatives and Use Thereof. WO2006075888, 2006.
63. Kozikowski, A. P.; Dritschilo, A.; Jung, M.; Petukhov, P.; Chen, B. Histone Deacetylase Inhibitors and Methods of Use Thereof. WO2005007091, 2005.
64. Scopes, D. I. C. Substituted Phenylurea Derivatives as HDAC Inhibitors. WO2004067480, 2004.
65. Marson, C. M.; Savy, P.; Rioja, A. S.; Mahadevan, T.; Mikol, C.; Veerupillai, A.; Nsubuga, E.; Chahwan, A.; Joel, S. P. Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxamides. J. Med. Chem. 2006, 49, 800-805.
66. Mai, A.; Massa, S.; Rotili, D.; Simeoni, S.; Ragno, R.; Botta, G.; Nebbioso, A.; Miceli, M.; Altucci, L.; Brosch, G. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J. Med. Chem. 2006, 49, 6046-6056.
67. Glenn, M. P.; Kahnberg, P.; Boyle, G. M.; Hansford, K. A.; Hans, D.; Martyn, A. C.; Parsons, P. G.; Fairlie, D. P. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J. Med. Chem. 2004, 47, 2984-2994.
68. Rossi, C.; Porcelloni, M.; D'Andrea, P.; Fattori, D.; Marastoni, E. Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them. WO2006097460, 2006.
69. Guidi, A.; Dimoulas, T.; Giannotti, D.; Harmat, N. N-Hydroxamides ω-Substituted with Tricyclic Groups as Histone Deacetylase Inhibitors, Their Preparation and Use in Pharmaceutical Formulations. WO2006097449, 2006.
70. Finn, P. W.; Bandara, M.; Butcher, C.; Finn, A.; Hollinshead, R.; Khan, N.; Law, N.; Murthy, S.; Romero, R.; Watkins, C.; Andrianov, V.; Bokaldere, R. M.; Dikovska, K.; Gailite, V.; Loza, E.; Piskunova, I.; Starchenkov, I.; Vorona, M.; Kalvinsh, I. Novel sulfonamide derivatives as inhibitors of histone deacetylase. Helv. Chim. Acta 2005, 88, 1630-1657.
71. (a) Kim, D.-K.; Lee, J. Y.; Kim, J.-S.; Ryu, J.-H.; Choi, J.-Y.; Lee, J. W.; Im, G.-J.; Kim, T.-K.; Seo, J. W.; Park, H.-J.; Yoo, J.; Park, J.-H.; Kim, T.-Y.; Bang, Y.-J. Synthesis and biological evaluation of 3-(4-substituted- phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 5745-5751.
72. (b) Kim, D.-K.; Lee, J. Y.; Lee, N. K.; Kim, J.-S.; Lee, J. W.; Lee, S. H.; Choi, J.-Y.; Ryu, J.-H.; Kim, N. H.; Im, G.-J.; Kim, T.-K.; Seo, J. W.; Bang, Y.-J. α,β-Unsaturated Hydroxamic Acid Derivatives and Their Use as Histone Deacetylase Inhibitors. WO200387066, 2003.
73. Urano, Y.; Satoh, S.; Ishibashi, N.; Kamijo, K. Hydroxamic acid Derivative as Histone Deacetylase (HDAC) Inhibitors. WO2004063169, 2004.
74. Bressi, J. C.; Brown, J. W.; Cao, S. X.; Gangloff, A. R.; Jennings, A. J.; Stafford, J. A.; Vu, P. H.; Xiao, X.-Y. Histone Deacetylase Inhibitors. WO2004082638, 2004.
75. Bressi, J. C.; Cao, S. X.; Gangloff, A. R.; Jennings, A. J.; Stafford, J. A. N-Hydroxy-3-(3-(1H-imidazol-2-yl)-phenyl)-acrylamide Derivatives and Related Compounds as Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer. WO2005065681, 2005.
76. Shinji, C.; Nakamura, T.; Maeda, S.; Yoshida, M.; Hashimoto, Y.; Miyachi, H. Design and synthesis of phthalimide-type histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2005, 7, 4427-4431.
77. Shinji, C.; Maeda, S.; Imai, K.; Yoshida, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. 2006, 8, 7625-7651.
78. Chen, D.; Deng, W.; Sangthongpitag, K.; Song, H. Y.; Sun, E. T.; Yu, N.; Zou, Y. Benzimidazole Derivatives: Preparation and Pharmaceutical Applications. WO2005028447, 2005.
79. 4 substitutions on biological activity. J. Med. Chem. 2004, 47, 1098-1109.
80. (b) Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottom, P.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J. Med. Chem. 2004, 47, 1351-1359.
81. (c) Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosh, G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxamides. J. Med. Chem. 2005, 46, 4826-4829.
82. Minucci, S.; Pelicci, P. G.; Mai, A.; Ballarini, M.; Gargiulo, G.; Massa, S. New Histone Deacetylase Inhibitors. WO2006037761, 2006.
83. (a) Maier, T.; Beckers, T.; Baer, T.; Gimmnich, P.; Dullweber, F.; Vennemann, M. Novel Amido-Substituted Hydroxy-6-phenylphenanthridines. WO2005087724, 2005.
84. (b) Maier, T.; Bär, T.; Beckers, T.; Leja, A.; Schneider, S.; Gekeler, V. N-Sulphonylpyrrole and Their Use as Histone Deacetylase. WO2006097474, 2006.
85. (c) Maier, T.; Beckers, T.; Hummel, R. P.; Feth, M.; Muller, M.; Bär, T. Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylase Inhibitors. WO2007039403, 2007.
86. Lee, K. C. L.; Sun, E. T. Imidazo[1,2-A]pyridine Derivatives: Preparation and Pharmaceutical Applications. WO2006101455, 2006.
87. (a) Groosmann, A.; Herting, F.; Koerner, M.; Kuenkele, K.-P.; Limberg, A.; Mundigl, O.; Tibes, U. Enantiomers of Thiophene Hydroxamic Acid Derivatives and Their Use as HDAC Inhibitors. WO200405499, 2004.
88. (b) Fertig, G.; Herting, F.; Koerner, M.; Kubbies, M.; Limberg, A.; Reiff, U.; Tibes, U. Hydroxamates, Their Manufacture and Use as Pharmaceutical Agents. WO2005121119, 2005.
89. (c) Fertig, G.; Herting, F.; Koerner, M.; Kubbies, M.; Limberg, A.; Reiff, U.; Tibes, U. Thiophene Hydroxamic Acid Derivatives and Their Use as HDAC Inhibitors. WO2005121120, 2005.
90. (d) Fertig, G.; Herting, F.; Koerner, M.; Kubbies, M.; Limberg, A.; Reiff, U.; Tibes, U. Thiophene Derivatives, Their Manufacture and Use As Pharmaceutical Agents. WO2005121134, 2005.
91. (a) Archer, J. A.; Bordogna, W.; Bull, R. J.; Clark, D. E.; Dyke, H. J.; Gill, M.; Harris, N. V.; Van Den Heuvel, M.; Price, S. Substituted Thienyl-hydroxamic Acids as Histone Deacetylase Inhibitors. WO2004013130, 2004.
92. (b) Bordogna, W.; Sutton, J. M.; Hynd, G.; Dyke, H. J.; Price, S.; Harris, N. V.; Gill, M. I. A. Thiazolyl-hydroxamic Acids and Thiadiazolyl-hydroxamic Acids, and Use Thereof for Treating Diseases Associated with Histone Deacetylase Enzymatic Activity. WO2005075469, 2005.
93. (c) Dyke, H. J.; Price, S.; Van Den Heuvel, M.; Sutton, J. M.; MacKenzie, R. E.; Heald, R. E. Substituted Thienyl-hydroxamic Acids Having Histone Deaceetylase Activity. WO2005014588, 2005.
94. (a) Price, S.; Bordogna, W.; Bull, R. J.; Clark, D. E.; Crackett, P. H.; Dyke, H. J.; Gill, M.; Harris, N. V.; Gorski, J.; Lloyd, J.; Lockey, P. M.; Mullett, J.; Roach, A. G.; Roussel, F.; White, A. B. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2- hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 370-375.
95. (b) Price, S.; Bordogna, W.; Braganza, R.; Bull, R. J.; Dyke, H. J.; Gardan, S.; Gill, M.; Harris, N. V.; Heald, R. A.; van den Heuvel, M.; Lockey, P. M.; Lloyd, J.; Molina, A. G.; Roach, A. G.; Roussel, F.; Sutton, J. M.; White, A. B. Identification and optimization of a series of substituted 5- pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 363-369.
96. Stunkel, W.; Wang, H.; Yin, Z. Biaryl Linked Hydroxamates: Preparation and Pharmaceutical Applications. WO2005040161, 2005.
97. Uesato, S.; Nagaoka, Y.; Yamori, T. N-Hydroxycarboxamide Derivative. WO2003070691, 2003.
98. Chakravarty, P. K.; Kuo, H.; Matthews, J. M.; Meinke, P. T. Inhibitors of Histone Deacetylase. WO2006017214, 2006.
99. Verner, E. J.; Sendzick, M.; Baskaran, C.; Buggy, J. J.; Robinson, J. Novel Hydroxamates as Therapeutic Agents. WO2004092115, 2004.
100. Lee, C. H.; Jung, H. J.; Kim, J. H.; Cho, J. M.; Ro, S. G.; Lee, T. G. Hyun, Y.-L.; Shin, D. K. Arylaminomethyl Propenyl Benzyhydroxamide Derivatives with Inhibitory Activity against Histone Deacetylase and Method for the Preparation Thereof. WO2006025683, 2006.
101. Anandan, S. K.; Xiao, X.-Y.; Ward, J. S.; Patel, D. V. Fused Heterocyclic Compounds Useful as Inhibitors of Histone Deacetylase. WO2006088949, 2006.
102. (a) Van Elemen, K.; Verdonck, M. G. C.; Van Brandt, S. F. A.; Angibaud, P. R.; Meerpoel, L.; Dyatkin, A. B. Novel Piperazinyl-arylhydroxamic Acid Derivatives and Their Use as Histone Deacetylase Inhibitors in the Treatment of Proliferative Disease. WO2003075929, 2003.
103. (b) Van Brandt, S. F. A.; Franciscus, A.; Van Elemen, K.; Angibaud, P. R.; Marconnet-Decrane, L.; Francoise, B.; Arts, J. New Substituted Propenyl Piperazine Derivatives as Novel Inhibitors of Histone Deacetylase. WO2006010749, 2006.
104. (c) Verdonck, M. G. C.; Gustaaf, C.; Angibaud, P. R.; Roux, B.; Pilatte, I.; Noelle, C.; Ten Holte, P.; Arts, J.; Van Elemen, K. Substituted Indolyl Alkyl Amino Derivatives as Novel Inhibitors of Histone Deacetylase. WO2006010750, 2006.
105. (d) Ten Holte, P.; Van Elemen, K.; Angibaud, P. R.; Marconnet-Decrane, L.; Francoise, B.; Meerpoel, L. Imidazolinone and Hydantoine Derivatives as Novel Inhibitors of Histone Deacetylase. WO2006136553, 2006.
106. Miller, T. A.; Witter, D. J.; Belvedere, S. Thiophene and Benzothiophene Hydroxamic Acid Derivatives. WO2005034880, 2005.
107. Bressi, J. C.; Gangloff, A. R.; Jennings, A. J. Histone Deacetylase Inhibitors. WO2005066151, 2005.
108. (a) Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977, 196, 441-444.
109. (b) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
110. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.-I.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317.
111. Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem. 2005, 48, 1019-1032.
112. Chen, B.; Petukhov, P. A.; Jung, M.; Velena, A.; Eliseeva, E.; Dritschilo, A.; Kozikowski, A. P. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1389-1392.
113. Gu, W.; Nusinzon, I.; Smith, R. D.; Horvath, C. M.; Silverman, R. B. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: potent inhibition of histone deacetylases. Bioorg. Med. Chem. 2006, 14, 3320-3329.
114. Bordogna, W.; Sutton, J. M.; Hynd, G.; Dyke, H. J.; Price, S.; Harris, N. V.; Gill, M. I. A. Thiazolyl-hydroxamic and Thiadiazolyl-hydroxamic Acids, and Use Thereof for Treating Diseases Associated with Histone Deacetylase Enzymatic Activity. WO2005075466, 2005.
115. Ai-Hua, X.; Bo-Yu, L.; Chen-Zhong, L.; Zhi-Bin, L.; Xian-Ping, L.; Le-Ming, S.; Jia-Ju, Z. Docking study of HDAC implication for benzamide inhibitors binding mode. Acta Phys.-Chim. Sin. 2004, 20, 569-572.
116. Moradei, O. M.; Mallais, T. C.; Frechette, S.; Paquin, I.; Tessier, P. E.; Leit, S. M.; Fournel, M.; Bonfils, C.; Tranchy-Bourget, M.-C.; Liu, J.; Yan, T. P.; Lu, A.-H.; Rahil, J.; Wang, J.; Lefebvre, S.; Li, Z.; Vaisburg, A. F.; Besterman, J. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem. 2007, 50, 5543-5546.
117. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999, 42, 3001-3003.
118. Vaisburg, A.; Bernstein, N.; Frechette, S.; Allan, M.; Abou-Khalil, E.; Leit, S.; Moradei, O.; Bouchain, G.; Wang, J.; Woo, S. H.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M. C.; Kalita, A.; Beaulieu, C.; Li, Z.; Mac Leod, A. R.; Besterman, J. M.; Delorme, D. (2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 283-287.
119. Moradei, O.; Leit, S.; Zhou, N.; Frechette, S.; Paquin, I.; Raeppel, S.; Gaudette, F.; Bouchain, G.; Woo, S. H.; Vaisburg, A.; Fournel, M.; Kalita, A.; Lu, A.; Trachy-Bourget, M. C.; Yan, P. T.; Liu, J.; Li, Z.; Rahil, J.; MacLeod, A. R.; Besterman, J. M.; Delorme, D. Substituted N-(2-amino-phenyl)- benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4048-4052.
120. (a) Fertig, G.; Herting, F.; Koerner, M.; Kubbies, M.; Limberg, A.; Reiff, U.; Weidner, M. Arylene-carboxylic Acid (2-Amino-phenyl)-amide Derivatives as Pharmaceutical Agents. WO2004052838, 2004.
121. (b) Fertig, G.; Herting, F.; Kubbies, M.; Limberg, A.; Reiff, U.; Weidner, M. Oxime Derivatives and Their Use as Pharmaceutically Active Agents. WO2004087693, 2004.
122. (c) Fertig, G.; Herting, F.; Kubbies, M.; Limberg, A.; Reiff, U.; Weidner, M. New Mono-acylated o-Phenylenediamines Derivatives. WO2004069803, 2004.
123. (d) Fertig, G.; Herting, F.; Kubbies, M.; Limberg, A.; Reiff, U.; Weidner, M. Novel N-Monoacylated o-Phenylenediamines, Their Condensed Heterocyclic Derivatives and Their Use as Pharmaceutical Agents. WO2004069133, 2004.
124. Grossmann, A.; Herting, F.; Koerner, M.; Kuenkele, K.-P.; Limberg, A.; Mundigl, O.; Tibes, U. Enantiomers of Thiophene Hydroxamic Acid Derivatives and Their Use as HDAC Inhibitors. WO200405999, 2004.
125. (a) Stokes, E.; Roberts, C.; Waring, M. Benzamide Derivatives Useful as Histone Deacetylase Inhibitors. WO2003087057, 2003.
126. (b) Stokes, E.; Waring, M.; Gibson, K. Inhibitors of Histone Deacetylase. WO2003092686, 2003.
127. (c) Stokes, E.; Carr, G. N-(2-Aminophenyl)-4-(5-((ethylamino) methyl)-1,3-thiazol-2-yl)benzamide and N-(2-Aminophenyl)-4-(5- ((isopropylamino)methyl)-1,3-thiazol-2-yl) benzamide as HDAC Inhibitors. WO2006064246, 2006.
128. (d) Gibson, K.; Stokes, E.; Waring, M.; Andrews, D.; Matusiak, Z.; Graham, M. Benzamide Compounds. WO2006024841, 2006.
129. (e) Gibson, K.; Stokes, E.; Waring, M.; Andrews, D.; Matusiak, Z.; Maybury, M.; Roberts, C. N-Phenyl-4-pyridin-2-yl-benzamide Derivatives as Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer. WO2006075160, 2006.
130. (f) Gibson, K.; Stokes, E.; Waring, M.; Andrews, D.; Matusiak, Z. Novel Benzamide Derivatives. WO2006077387, 2006.
131. (a) Moradei, O.; Paquin, I.; Leit, S.; Frechette, S.; Vaisburg, A.; Besterman, J.; Tessier, P; Mallais, T. Inhibitors of Histone Deacetylase. WO2005030704, 2005.
132. (b) Moradei, O.; Paquin, I.; Leit, S.; Fréchette, S.; Vaisburg, A.; Besterman, J.; Tessier, P; Mallais, T. Inhibitors of Histone Deacetylase. WO2005030705, 2005.
133. Nagaoka, Y.; Maeda, T.; Kawai, Y.; Nakashima, D.; Oikawa, T.; Shimoke, K.; Ikeuchi, T.; Kuwajima, H.; Uesato, S. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives. Eur. J. Med. Chem. 2006, 41, 697-708.
134. Lu, X. P.; Li, Z.; Xie, A.; Li, B.; Ning, Z.; Shan, S.; Deng, T.; Hu, W. Histone Deacetylase Inhibitors of Novel Benzamide Derivatives with Potent Differentiation and Anti-Proliferation Activity. WO200-4071400, 2004.
135. (a) Bressi, J. C.; Brown, J.; Gangloff, A. R.; Jennings, A. J.; Kaldor, S. W.; Skene, R. J.; Stafford, J. A.; Vu, P. H. Histone Deacetylase Inhibitors. WO2006066133, 2006.
136. (b) Bressi, J. C.; Brown, J.; Gangloff, A. R.; Stafford, J. A.; Vu, P. H. Histone Deacetylase Inhibitors. WO2006122319, 2006.
137. (c) Bressi, J. C.; Gangloff, A. R.; Kwok, L. Histone Deacetylase Inhibitors. WO2007011626, 2007.
138. Wang, Y.; Li, T.; Mull, E. Indane Amides with Antiproliferative Activity. WO2006062580, 2006.
139. Siliphaivanh, P.; Harrington, P.; Witter, D. J.; Otte, K.; Tempest, P.; Kattar, S.; Kral, A. M.; Fleming, J. C.; Deshmukh, S. V.; Harsch, A.; Secrist, P. J.; Miller, T. A. Design of novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett, 2007, 17, 4619-4624.
140. (a) Frey, R. R.; Wada, C. K.; Garland, R. B.; Curtin, M. L.; Michaelides, M. R.; Li, J.; Pease, L. J.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Murphy, S. S.; Davidsen, S. K. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 2002, 12, 3443-3447.
141. (b) Wada, K. C.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Garland, R. B.; Holms, J. H.; Li, J.; Pease, L. J.; Guo, J.; Glaser, K. B.; Marcotte, P. A.; Richardson, P. L.; Murphy, S. S.; Bouska, J. J.; Tapang, P.; Magoc, T. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. α-Keto amides as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 2003, 13, 3331-3335.
142. (c) Vasudevan, A.; Ji, Z.; Frey, R. R.; Wada, K. C.; Steinman, D.; Heyman, H. R.; Guo, Y.; Curtin, M. L.; Guo, J.; Li, J.; Pease, L.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 2003, 13, 3909-3913.
143. (a) Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P. T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Serafini, S.; Steinkuhler, C. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 59485952.
144. (b) Chakravarty, P. K.; Colletti, S. L.; Ingenito, R.; Jones, P.; Meinke, P. T.; Muraglia, E.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Steinkuhler, C. Amides Derivatives as Inhibitors of Histone Deacetylase. WO2006005941, 2006.
145. (c) Chakravarty, P. K.; Colletti, S. L.; Ingenito, R.; Jones, P.; Meinke, P. T.; Petrocchi, A.; Steinkuhler, C. Amides Derivatives as Inhibitors of Histone Deacetylase. WO2006005955, 2006.
146. Hu, E.; Dul, E.; Sung, C.-M.; Chen, Z.; Kirkpatrick, R.; Zhang, G.-F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; de los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 2003, 307, 720-728.
147. Nakao, Y.; Yoshida, S.; Matsunaga, S.; Shindoh, N.; Terada, Y.; Nagai, K.; Yamashita, J. K.; Ganesan, A.; van Soest, R. W. M.; Fusetani, N. Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. Angew. Chem., Int. Ed. 2006, 45, 7553-7557.
148. Oku, N.; Nagai, K.; Shindoh, N.; Terada, Y.; van Soest, R. W. M.; Matsunaga, S.; Fusetani, N. Three new cyclostellettamines, which inhibit histone deacetylase from a marine sponge of the genus Xestospongia. Bioorg. Med. Chem. Lett. 2004, 14, 2617-2620.
149. Davis, D.; Kim, H. M.; Ramphal, J. Y.; Spencer, J. R.; Tai, V. W. F.:, Verner, E. J. Silanol Derivatives as Inhibitors of Histone Deacetylase. WO2006069096, 2006.
150. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer 2007, 121, 1138-1148.
151. Maulucci, N.; Chini, M. G.; Di Micco, S.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M. C.; Casapullo, A.; Riccio, R.; Bifulco, G.; De Riccardis, F. Molecular insights into azumamide E histone deacetylases inhibitory activity. J. Am. Chem. Soc. 2007, 129, 3007-3012.
152. Park, J.-H.; Jung, Y.; Kim, T. Y.; Kim, S. G.; Jong, H.-S.; Lee, J. W.; Kim, D.-K.; Lee, J.-S.; Kim, N. K.; Kim, T.-Y.; Bang, Y.-J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 2004, 10, 5271-5281.
153. Inoue, S.; Mai, A.; Dyer, M. J. S.; Cohen, G. M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006, 66, 6785.
154. Neidle, S.; Thurston, D. E. Chemical approaches to the discovery and development of cancer therapies. Nat. Rev. Cancer 2005, 5, 285-296.
155. Kim, M. S.; Blake, M.; Baek, J. H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63, 7291-7303.
156. Marchion, D. C.; Bicaku, E.; Daud, D. I.; Richon, V.; Sullivan, D. M.; Munster, P. N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J. Cell. Biochem. 2004, 92, 223-237.
157. Marchion, D. C.; Bicaku, E.; Daud, A. I.; Sullivan, D. M.; Munster, P. N. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther. 2005, 4, 1993-2000.
158. Glaser, K. B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 2007, 74, 659-671.
159. (a) Savickiene, J.; Treigyte, G.; Borutinskaite, V.; Navakauskiene, R.; Magnusson, K. E. The histone deacetylase inhibitor FK228 distinctly sensitize the human leukemia cells to retinoic acid induced differentiation. Ann. NY. Acad. Sci. 2006, 1091, 368-384.
160. (b) De los Santos, M.; Zambrano, A.; Aranda, A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol. Cancer Ther. 2007, 6, 1425-1432.
161. (c) Borutinskaite, V.; Navakauskiene, R.; Magnusson, K. E. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann. N.Y. Acad. Sci. 2006, 1091, 346-355.
162. (d) Kato, Y.; Salumbides, B. C.; Wang, X. F.; Qian, D. Z.; Williams, S.; Wei, Y.; Sanni, T. B.; Atadja, P.; Pili, R. Antitumor effect of the histone deacetylase LAQ824 in combinaton with 13-cis-retinoic acid in human malignant melanoma. Mol. Cancer Ther. 2007, 6, 70-81.
163. Nimmanapalli, R.; Fuino, L.; Stobaugh, C.; Richon, V.; Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101, 3236-3239.
164. Fiskus, W.; Pranpat, M.; Balasis, M.; Bali, P.; Estrella, V.; Kumaraswamy, S.; Rao, R.; Rocha, K.; Herger, B.; Lee, F.; Richon, V.; Bhalla, K. Cotreatment with vorinostat (suberoyl hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 2006, 12, 5869-5878.
165. Maggio, S. C.; Rosato, R. R.; Kramer, L. B.; Dai, Y.; Rahamani, M.; Paik, D. S.; Czarnik, A. C.; Payne, S. G.; Spiegel, S.; Grant, S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004, 64, 2590-2600.
166. Yu, C.; Rahamani, M.; Conrad, D.; Subler, M.; Dent, P.; Grant, S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003, 102, 3765-3774.
167. Rahmani, M.; Yu, C.; Dai, Y.; Reese, E.; Ahmed, W.; Dent, P.; Grant, S. Coadministration of heat shock protein 90 antagonist 17-allyamino-17- demethoxygeladnamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 2003, 63, 8420-8427.
168. Sharma, D.; Saxena, N. K.; Davidson, N. E.; Vertino, P. M. Restoration of tamoxifen sensitivity in estrogen-receptor negative breast cancer cells: tamoxifen-bound ER recruits distinctive coprepressor complexes in response to deacetylase inhibition by valproic acid and trichostatin A. Cancer Res. 2006, 66, 6370-6378.
169. Lee, J.-H.; Park, J.-H.; Jung, Y.; Kim, J.-H.; Jong, H.-S.; Kim, T. I. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating fhymidylate synthase in human cancer cells. Mol. Cancer Ther. 2006, 5, 3085-3095.
170. Munshi, A.; Tanaka, T.; Hobbs, M. L.; Tucker, S. L.; Richon, V. M.; Meyen, R. E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol. Cancer Ther. 2006, 5, 1967-1974.
171. (a) Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; McGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Sher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588.
172. (b) Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; Richrdson Schu, E.; Olgac, S.; Marks, P. A.; Scher, H.; Richon, V. M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931.
173. (c) Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J. H.; Reilly, J. F.; Ricker, J. L.; Richon, V. M.; Frankel, S. R. Phase 2 trial of oral vorinostat (suberoyl hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109, 31-39.
174. (a) Byrd, J. C.; Marcucci, G.; Parthun, M. R.; Xiao, J. J.; Klisovic, R. B.; Moran, M.; Lin, T. S.; Liu, S.; Sklenar, A. R.; Davis, M. E.; Lucas, D. M.; Fisher, B.; Shank, R.; Tejaswi, S. L.; Binkley, P.; Wright, J.; Chan, K. K.; Grever, M. R. A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105, 959-967.
175. (b) Piekarz, R. L.; Frye, A. R.; Wright, J. J.; Steinberg, S. M.; Liewehr, D. J.; Rosing, D. R.; Sachdev, V.; Fojo, T.; Bates, S. E. Cardiac studies in patients treated with depsipeptide FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res. 2006, 12, 3762-3773.
176. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23, 3912-3922.
177. Giles, F.; Fischer, T.; Cortes, J.; Garcia-Manero, G.; Beck, J.; Ravandi, F.; Masson, E.; Rae, P.; Laird, G.; Sharma, S.; Kantarjian, H.; Dugan, M.; Albitar, M.; Bhalla, K. A phase I study of intravenous LBH589, a novel cinammic hydroxamid acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2006, 12, 4628-4635.
178. (a) Garcia-Manero, G.; Kantarjiann, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W. G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'Brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J. P. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108, 3271-3279.
179. (b) Kuendgen, A.; Knipp, S.; Fox, F.; Strupp, C.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Gattermann, N. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodisplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol. 2005, 84, 61-66.
180. Munster, P.; Marchion, D.; Bicaku, E.; Schmitt, M.; Lee, J. H.; DeConti, R.; Simon, G.; Fishman, M.; Minton, S.; Garret, C.; Chiappori, A.; Lush, R.; Sullivan, D.; Daud, A. Phase I trial of histone deacetylase inhibition by valproic acid followed by topoisomerase II inhibitor epirubicin in advanced solid tumor: a clinical and translational study. J. Clin. Oncol. 2007, 25, 1979-1985.